Related Experiment Video
Updated: Jun 28, 2025

Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture
Published on: August 25, 2022
Glioblastoma modeling with 3D organoids: progress and challenges
Xin Wang1, Yusha Sun2, Daniel Y Zhang3
1Department of Neuroscience and Mahoney Institute for Neurosciences, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
Glioblastoma (GBM) is the most aggressive adult primary brain tumor with nearly universal treatment resistance and recurrence. The mainstay of therapy remains maximal safe surgical resection followed by concurrent radiation therapy and temozolomide chemotherapy. Despite intensive investigation, alternative treatment options, such as immunotherapy or targeted molecular therapy, have yielded limited success to achieve long-term remission. This difficulty is partly due to the lack of pre-clinical models that fully recapitulate the intratumoral and intertumoral heterogeneity of GBM and the complex tumor microenvironment. Recently, GBM 3D organoids originating from resected patient tumors, genetic manipulation of induced pluripotent stem cell (iPSC)-derived brain organoids and bio-printing or fusion with non-malignant tissues have emerged as novel culture systems to portray the biology of GBM. Here, we highlight several methodologies for generating GBM organoids and discuss insights gained using such organoid models compared to classic modeling approaches using cell lines and xenografts. We also outline limitations of current GBM 3D organoids, most notably the difficulty retaining the tumor microenvironment, and discuss current efforts for improvements. Finally, we propose potential applications of organoid models for a deeper mechanistic understanding of GBM and therapeutic development.
Insights
Glioblastoma (GBM) research benefits from novel 3D organoid models that better mimic tumor complexity than traditional methods. These advanced models offer new avenues for understanding GBM biology and developing effective therapies.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Biotechnology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis and treatment resistance.
- Current therapies (surgery, radiation, chemotherapy) offer limited long-term remission.
- Existing preclinical models fail to fully capture GBM's heterogeneity and microenvironment.
Purpose of the Study:
- To review methodologies for generating Glioblastoma (GBM) 3D organoids.
- To discuss insights gained from GBM organoid models compared to traditional models.
- To outline limitations and future directions for GBM organoid development.
Main Methods:
- Generation of GBM organoids from patient tumors.
- Genetic manipulation of induced pluripotent stem cell (iPSC)-derived brain organoids.
- Bio-printing and fusion with non-malignant tissues.
Main Results:
- GBM organoids provide a more accurate representation of tumor biology than cell lines or xenografts.
- Organoid models reveal insights into intratumoral and intertumoral heterogeneity.
- Challenges remain in fully recapitulating the tumor microenvironment in current organoid systems.
Conclusions:
- 3D Glioblastoma (GBM) organoids represent a significant advancement in preclinical modeling.
- Further refinement is needed to incorporate the tumor microenvironment for comprehensive study.
- Organoid models hold promise for advancing GBM mechanistic understanding and therapeutic development.

